Register entry
GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 25
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
25| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8511304 | BREO ELLIPTAfluticasone furoate; vilanterol trifenatate | product | Jun 2027 |
| 8511304*PED | BREO ELLIPTAfluticasone furoate; vilanterol trifenatate | use | Dec 2027 |
| 7488827 | INCRUSE ELLIPTAumeclidinium bromide | substance, product | Dec 2027 |
| 11116721 | BREO ELLIPTAfluticasone furoate; vilanterol trifenatate | product | Feb 2029 |
| 11116721*PED | BREO ELLIPTAfluticasone furoate; vilanterol trifenatate | use | Aug 2029 |
| 8534281 | BREO ELLIPTAfluticasone furoate; vilanterol trifenatate | product | Mar 2030 |
| 8534281*PED | BREO ELLIPTAfluticasone furoate; vilanterol trifenatate | use | Sept 2030 |
| 8746242 | BREO ELLIPTAfluticasone furoate; vilanterol trifenatate | product | Oct 2030 |
| 8746242*PED | BREO ELLIPTAfluticasone furoate; vilanterol trifenatate | use | Apr 2031 |
| Product | Exclusivity | Until |
|---|---|---|
| BREO ELLIPTAFLUTICASONE FUROATE; VILANTEROL TRIFENATATE | PED Paediatric | Nov 2026 |
Enquiry
Common questions
- Is GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE FDA approved?
- GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.